Averitas Pharma, Inc. clinical trials
Acquired by Grünenthal GmbH, 2018 · source ↗
The registry lists 2 studies whose lead sponsor is Averitas Pharma, Inc.. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 21, 2026.
Before and after it joined Grünenthal GmbH
- First submitted before Averitas Pharma, Inc. became part of Grünenthal GmbH
- 0
- First submitted after Averitas Pharma, Inc. became part of Grünenthal GmbH
- 2
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Phase
- Phase 3
- 1
Registry sponsor names on this page
- Averitas Pharma, Inc.2 studies
Something wrong with this grouping? Tell us on the Grünenthal GmbH page.
Studies
Recruiting first, then most recently updated. Showing 2 of 2. All Grünenthal GmbH studies →
- Comparison of Qutenza (8% Capsaicin) With a Low-dose Capsaicin for Treatment of Nerve Pain After SurgeryCompletedNCT04967664Phase 3
Sponsor listed in the registry: Averitas Pharma, Inc. · First submitted after Averitas Pharma, Inc. became part of Grünenthal GmbH
- Observational Study to Evaluate the Efficacy of Sustained QUTENZA® Use in Painful Diabetic Peripheral NeuropathyActive, not recruitingNCT06495424
Sponsor listed in the registry: Averitas Pharma, Inc. · First submitted after Averitas Pharma, Inc. became part of Grünenthal GmbH